Nonalcoholic Steatohepatitis (NASH)
Conditions
Brief summary
This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of HEC96719, in healthy subjects.This study is the healthy adult subjects single ascending-dose research
Detailed description
This study will evaluate the safety and tolerability of escalating single oral doses of HEC96719, and characterize the single-dose pharmacokinetics (PK) of HEC96719. Participants will receive either HEC96719 or HEC96719 placebo.
Interventions
DRUGHEC96719 tablets
0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
DRUGPlacebo tablet
0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
Sponsors
Sunshine Lake Pharma Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Willing to participate in the study, able to understand and sign the informed consent, and able to complete the the study in accordance with the requirements of the study. * Female subjects who are not pregnant or lactating and male subjects whose female partners are fertile shall voluntarily take effective contraceptive measures from the date of signing the informed consent form to 3 months after the medication. * When signing the informed consent, 18 years old ≤the age≤45 years old(including the critical value), gender is not limited. * Male body weight ≥50kg, female body weight ≥45kg, and body mass index (BMI) in the range of 18-28 kg/m2 (including the critical value). * No clinical significance of vital signs, physical examination, laboratory examination, electrocardiogram, ultrasound abdomen and chest X-ray (posterior and anterior) results.
Exclusion criteria
* Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis. * Those who are known to have allergy history or allergy constitution to the test preparation and any of its components or related preparations. * Intemperant or regular drinkers within 3 months prior to the study, i.e., those who consumed more than 21 units of alcohol per week (1 unit =360mL beer or 45mL spirit with 40% alcohol or 150mL wine), or those who were positive on the alcohol breath test. * Those who had a blood donation or blood loss of \>400mL within one month before taking the study drug. * Those who have participated in clinical trials of other drugs within 3 months before randomization. * Subjects considered by the investigator to have other factors unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events of the single ascending-dose | From the baseline to day7 | To assess the safe and tolerability of the single ascending-dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | At pre-defined intervals from Days 1-2 | Maximum Plasma Concentration(Cmax)of HEC96719 in single ascending dose |
| AUC | At pre-defined intervals from Days 1-2 | Area Under the Curve(AUC) of HEC96719 in single ascending dose |
| Tmax | At pre-defined intervals from Days 1-2 | Maximum Peak Time(Tmax) of HEC96719 in single ascending dose |
| T1/2 | At pre-defined intervals from Days 1-2 | Terminal elimination half-life(T1/2) of HEC96719 in single ascending dose |
Countries
China
Outcome results
None listed